123 related articles for article (PubMed ID: 21216595)
1. DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.
Clapham KM; Bardos J; Finlay MR; Golding BT; Griffen EJ; Griffin RJ; Hardcastle IR; Menear KA; Ting A; Turner P; Young GL; Cano C
Bioorg Med Chem Lett; 2011 Feb; 21(3):966-70. PubMed ID: 21216595
[TBL] [Abstract][Full Text] [Related]
2. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).
Desage-El Murr M; Cano C; Golding BT; Hardcastle IR; Hummersome M; Frigerio M; Curtin NJ; Menear K; Richardson C; Smith GC; Griffin RJ
Bioorg Med Chem Lett; 2008 Sep; 18(17):4885-90. PubMed ID: 18678488
[TBL] [Abstract][Full Text] [Related]
3. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
[TBL] [Abstract][Full Text] [Related]
5. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).
Cano C; Golding BT; Haggerty K; Hardcastle IR; Peacock M; Griffin RJ
Org Biomol Chem; 2010 Apr; 8(8):1922-8. PubMed ID: 20449499
[TBL] [Abstract][Full Text] [Related]
6. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Griffin RJ; Fontana G; Golding BT; Guiard S; Hardcastle IR; Leahy JJ; Martin N; Richardson C; Rigoreau L; Stockley M; Smith GC
J Med Chem; 2005 Jan; 48(2):569-85. PubMed ID: 15658870
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.
Ihmaid S; Al-Rawi J; Bradley C; Angove MJ; Robertson MN; Clark RL
Bioorg Med Chem; 2011 Jul; 19(13):3983-94. PubMed ID: 21664823
[TBL] [Abstract][Full Text] [Related]
8. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
Leahy JJ; Golding BT; Griffin RJ; Hardcastle IR; Richardson C; Rigoreau L; Smith GC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6083-7. PubMed ID: 15546735
[TBL] [Abstract][Full Text] [Related]
9. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
[TBL] [Abstract][Full Text] [Related]
10. Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors.
Payne SL; Rodriguez-Aristegui S; Bardos J; Cano C; Golding BT; Hardcastle IR; Peacock M; Parveen N; Griffin RJ
Bioorg Med Chem Lett; 2010 Jun; 20(12):3649-53. PubMed ID: 20472428
[TBL] [Abstract][Full Text] [Related]
11. DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
Cano C; Barbeau OR; Bailey C; Cockcroft XL; Curtin NJ; Duggan H; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Knights C; Menear KA; Newell DR; Richardson CJ; Smith GC; Spittle B; Griffin RJ
J Med Chem; 2010 Dec; 53(24):8498-507. PubMed ID: 21080722
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.
Ihmaid SK; Al-Rawi JM; Bradley CJ; Angove MJ; Robertson MN
Eur J Med Chem; 2012 Nov; 57():85-101. PubMed ID: 23059543
[TBL] [Abstract][Full Text] [Related]
13. Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors.
Aristegui SR; El-Murr MD; Golding BT; Griffin RJ; Hardcastle IR
Org Lett; 2006 Dec; 8(26):5927-9. PubMed ID: 17165896
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure elucidation, DNA-PK, PI3K, anti-platelet and anti-bacteria activity of linear 5, 6, and 10-substituted-2-morpholino-chromen-oxazine-dione and angular 3, 4, 6-substituted-8-morpholino-chromen-oxazine-2,10-dione.
Morrison R; Al-Rawi JM
J Enzyme Inhib Med Chem; 2016; 31(sup2):86-95. PubMed ID: 27255290
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.
Saifuzzaman M; Morrison R; Zheng Z; Orive S; Hamilton J; Thompson PE; Al-Rawi JMA
Bioorg Med Chem; 2017 Oct; 25(20):5531-5536. PubMed ID: 28838830
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
17. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening.
Park H; Lee S; Hong S
Bioorg Med Chem Lett; 2012 Aug; 22(15):4946-50. PubMed ID: 22771009
[TBL] [Abstract][Full Text] [Related]
18. Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors.
Ihmaid S; Ahmed HEA; Al-Sheikh Ali A; Sherif YE; Tarazi HM; Riyadh SM; Zayed MF; Abulkhair HS; Rateb HS
Bioorg Chem; 2017 Jun; 72():234-247. PubMed ID: 28482264
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
20. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
